Cell and Gene Outsourcing

1. Automating Cell Therapy Manufacturing And Enabling Rapid Multi-Site Tech Transfer 8/27/2025

   Find out how automating cell therapy manufacturing with a flexible platform can improve biological performance, streamline tech transfer, and support regulatory confidence for scalable, multi-site production.

2. Enabling CTA Submission In Record Time: Adenovirus Program Success 8/25/2025

   What does it take to bring an adenovirus-based therapy to the clinic – faster and without compromising quality? Find actionable insights to help improve efficiency and accelerate development timelines.

3. Four Pivotal Categories To Elevate Your Clinical Vendor Management 8/22/2025

   For sponsors ready to improve vendor management, technology platforms with the right framework can help you tighten budget controls, improve data integrity, or foster collaborative vendor relationships.

4. The Defensiveness Trap In Vendor Selection And Management 8/22/2025

   In clinical research, sponsor–vendor relationships are often framed as negotiations. Yet while both sides want to achieve a successful study, the process often becomes a tug-of-war.

5. Donor-To-Dose Solutions For Scalable Cell Therapy Manufacturing 8/21/2025

   From enabling earlier insights through donor characterization to reducing manufacturing variability through cell separation technologies, explore real-world case studies and actionable approaches to scale smarter.

6. Enabling Advanced Bioprocessing: Solutions That Challenge The Status Quo 8/20/2025

   Discover how innovative solutions can reduce production time, cut costs, and improve yields to ensure exceptional product quality at every stage of biologic drug development.

7. Solving Aseptic Filling Challenges For Your Advanced Therapeutics 8/20/2025

   Explore aseptic filling workcells, modalities, agency approvals, and insights from six expert users that offer a peer-driven look at industry innovation and benchmarks.

8. The Continuation Of A Journey 8/19/2025

   One family managed to combine resources and people to get an investigational gene replacement therapy manufactured and approved by the FDA so their daughter could be dosed just 14 months from her diagnosis.

9. Streamline AAV-Based Gene Therapies With Off-The-Shelf Plasmids 8/14/2025

   Standardized, well-characterized plasmids and streamlined platform processes can significantly accelerate viral vector development, improve consistency, and support scalable, high-quality gene therapy manufacturing.

10. Regulatory Strategy And Submission Support 8/13/2025

    This Regulatory Operations Team enables biotech and pharmaceutical companies to focus on innovation while ensuring a smooth, compliant path to market entry.